A synthetic form of rocaltrol prescribing information reviews link 1,dihydroxyvitamin D3the most physiologically active metabolite of vitamin D, has shown efficacy in the treatment of postmenopausal osteoporosis and promise in corticosteroid-induced osteoporosis.
Although results of small studies investigating calcitriol in the treatment of postmenopausal osteoporosis have been conflicting, a clinical trial in women with postmenopausal osteoporosis demonstrated toxicity what is aspirin patients with mild to moderate disease who received rocaltrol prescribing information reviews 0.
Reviews patients commencing long rocaltrol prescribing information reviews rocaltrol rocaltrol prescribing information information reviews with prednisone or prednisolone, calcitriol 0. Overall, calcitriol is well tolerated. The narrow here window' of calcitriol requires that its use be adequately supervised, with periodic monitoring of serum calcium and creatinine levels.
However, significant renal toxicity has not been seen in patients with osteoporosis treated with calcitriol in high dosages for several years in comparative and noncomparative trials.
In conclusion, article source with rocaltrol prescribing information reviews drugs currently used in the management of patients with osteoporosis, questions remain to be answered regarding rocaltrol prescribing information reviews efficacy of calcitriol relative to other agents, and its tolerability in such patients during the very long term. Nonetheless, at this rocaltrol prescribing information reviews, calcitriol should be rocaltrol prescribing information reviews a useful treatment option in patients with mild to moderate postmenopausal osteoporosis.
Medically reviewed on May 1, Rocaltrol calcitriol is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body.
Full Prescribing Information for Rocaltrol. If hypercalcemia develops in a patient receiving Rocaltrol, treatment should be immediately discontinued. In treating chronic hypocalcemia and resultant metabolic bone disease in patients undergoing chronic dialysis, the optimal dose must be carefully determined for each patient.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser. Welcome to Universal Drugstore.
2018 ©